No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Biotechnology
Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical firm, concentrating its efforts on discovering, developing, and commercializing medical treatments for individuals suffering from conditions in endocrinology, neurology, and gastroenterology. The company's current commercial offerings include Gvoke, a pre-mixed liquid glucagon formulated for managing severe hypoglycemia. It also provides Keveyis, a specific therapy for various forms of primary periodic paralysis, including hyperkalemic and hypokalemic types. Additionally, Xeris markets Recorlev, a cortisol synthesis inhibitor approved for adults experiencing endogenous hypercortisolemia as a result of Cushing's syndrome. Beyond its existing portfolio, Xeris Biopharma maintains an active pipeline of development programs. These initiatives aim to broaden the indications and potential applications of its current therapies, as well as to introduce novel products. The creation of these new offerings is supported by the company's proprietary formulation platforms, XeriSol and XeriJect. Established in 2005, the company's corporate headquarters are situated in Chicago, Illinois.
www.xerispharma.comNo one on the platform currently holds 0A8E.L.
No tracked institution reports a position in 0A8E.L as of their last filing.
No one on the platform has traded 0A8E.L yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 15.5% | — | — | — | ||
| Rev. Growth % | 43.7% | 70.2% | ||||
| Profit Margin % | 0.2% | -79.6% | -1087.3% | |||
| Free Cash Flow Margin % | 9.6% | -65.6% | -1011.3% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $387M | +34.4% | $-0.04 | $-0.04–$-0.04 | — | 1 |
| 2027 | $481M | +24.1% | $0.36 | $0.35–$0.38 | — | 1 |
| 2028 | $552M | +14.8% | $0.58 | $0.56–$0.61 | — | 1 |
| 2029 | $643M | +16.4% | $0.90 | $0.87–$0.95 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 4 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-06 | $0.01 | $-0.18 | -1582.7% |
| 2026-05-07 | $-0.00 | $0.01 | +465.0% |
| 2026-03-02 | $0.02 | $0.06 | +191.0% |
| 2025-11-06 | $0.01 | $0.00 | -38.9% |
| 2025-08-07 | $-0.03 | $-0.01 | +56.8% |
| 2025-05-08 | $-0.05 | $-0.06 | -21.3% |
| 2025-03-06 | $-0.06 | $-0.03 | +38.5% |
| 2024-11-08 | $-0.09 |
| $-0.11 |
| -26.9% |
| $1.8B |
| — |
| 0JBU.LIntellia Therapeutics, Inc. | $11.51 | +0.44% | $1.3B | — |
| 0K1R.LViridian Therapeutics, Inc. | $21.90 | +1.44% | $2.0B | — |
Source: Financial Modeling Prep · peers by sector/industry